A strength of this analysis is that the SPOTLIGHT and GLOW studies represent the largest sources to date for data on the global prevalence of CLDN18.2 positivity in patients with HER2-negative, LA unresectable or mG/GEJ adenocarcinoma. Here, CLDN18 is linked to gastroesophageal junction adenocarcinoma.